12 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
)
7 ClinicalTrials.gov. Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP. July 24, 2023. Last accessed May 2024
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome. ClinicalTrials.gov. Published June 25, 2021. Last accessed
Takeda Expands Partnership With Partners In Health To Address Social Determinants Of Health And Improve Access To Care In Massachusetts
TAK
11 Jun 24
HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema
TAK
6 Jun 24
treatment needs by enabling effortless data access and rapid insight generation. DARWEN™ has the capacity to harness electronic medical record
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
PFE
TAK
1 Jun 24
access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post
bmosu3jsvqltapvmajn7rgrwv31c2gznqhj2oqz6vm3q
TAK
31 May 24
/en/disease/detail/93583. Accessed May 2024
Zheng XL et al. J Thromb Haemost. 2020;18(10):2486
zqtvvt1bn9sbbfyax8c5fe 38lg
TAK
16 May 24
living with a post-transplant cytomegalovirus (CMV) infection to have public access to treatment
a9g7rdpnvm3 ktp
ACIU
TAK
13 May 24
webcast will also be accessible in the Investors section of the Company's website
279uicoe02p2aly4mi4t9s3p1e27 yai8fpknmbikfqitpkv92
ACIU
TAK
13 May 24
via webcast.
A live and archived webcast will also be accessible in the Investors section
zvzcidz6iphgqsoshengbfwv mvbhxa
TAK
22 Apr 24
companies, and start-up companies across Japan to enable access to potentially
39h jm9k87bo2tb7j4roq33fiy1sh92uy6
TAK
18 Apr 24
/entyvio-epar-product-information_en.pdf. Last updated: April 2023. Last accessed: January 2024
cqn2lz8eo41cxips69gm943wjj9v6xahllf16qsmep83218z21
TAK
27 Mar 24
. Last accessed Nov 2023
2- Ng SC
- Prev
- 1
- Next